Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$113.07

0.33 (0.29%)

06:33
11/25/16
11/25
06:33
11/25/16
06:33

Johnson & Johnson: NICE reverses decision on CDF leukaemia drug after price drop

Hundreds of people could benefit as NICE decision means ibrutinib can come off the Cancer Drugs Fund and be routinely available to treat chronic lymphocytic leukaemia. Ibrutinib will be available as a routine option for an estimated 620 patients with chronic lymphocytic leukaemia who have had treatment before, or who have genetic changes - known as 17p deletion or TP53 mutation. An earlier recommendation by NICE did not recommend ibrutinib, also known as Imbruvica, for routine NHS use. However, following a reduction in price, the independent appraisal committee were able to approve the drug as cost effective. Reference Link

JNJ Johnson & Johnson
$113.07

0.33 (0.29%)

10/18/16
UBSW
10/18/16
NO CHANGE
Target $137
UBSW
Buy
Johnson & Johnson robust pipeline underappreciated, says UBS
UBS analyst Matt Miksic said the Johnson & Johnson pipeline remains robust and is underappreciated. The analyst said the recent launch of biosimilars removes uncertainty and should be positive for the stock. He also expects the additional deployment of the company's capital - to expand its pipeline through in-licensing, partnerships or mid-sized acquisitions - to be incremental to his Buy thesis. Miksic has a $137 price target on Johnson & Johnson shares.
10/19/16
LEER
10/19/16
NO CHANGE
Target $140
LEER
Outperform
Johnson & Johnson should be bought on weakness, says Leerink
Leerink analyst Danielle Antalffy believes the recent selloff in Johnson & Johnson's shares was overdone and would recommend buying on weakness. The analyst views the company as well-equipped to manage the inevitable Remicade headwind and continues to believe Johnson & Johnson can drive improving top-line growth in 2017. She reiterates an Outperform rating and $140 price target on the shares.
10/19/16
UBSW
10/19/16
NO CHANGE
Target $144
UBSW
Buy
Johnson & Johnson has potential upside from expanding pipeline, says UBS
UBS analyst Matt Miksic noted Johnson & Johnson delivered a solid quarter and said he believes there is upside to his Buy thesis. The analyst cited the company's expanding pipeline, capital allocation strategy, and contracting across its broad portfolio and patient assistance programs is expected to help mitigate pressure from biosimilar competition. Miksic reiterated his Buy rating and raised his price target to $144 from $137 on Johnson & Johnson shares.
11/09/16
RBCM
11/09/16
NO CHANGE
RBCM
Johnson & Johnson should be bought on recent weakness, says RBC Capital
After meeting with J&J's VP, Investor Relations, RBC Capital analyst Glenn Novarro says that the company's Q3 pharma results indicate that the growth of its major drugs can more than offset any declines in Remicade sales next year. The analyst quotes J&J as saying that it has not been using price hikes to increase its sales, and he thinks that the company's diverse business model will allow it to avoid being hurt by any regulatory pressures. He is upbeat on the company's efforts to increase its margins and notes that its medical device results have improved. Novarro keeps a $133 price target and an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

GOOG

Alphabet

$762.52

12.02 (1.60%)

, GOOGL

Alphabet Class A

$778.22

13.76 (1.80%)

10:55
12/06/16
12/06
10:55
12/06/16
10:55
Hot Stocks
Google Wifi now available for purchase »

According to an email by…

GOOG

Alphabet

$762.52

12.02 (1.60%)

GOOGL

Alphabet Class A

$778.22

13.76 (1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

VLKAY

Volkswagen

$27.98

0.8 (2.94%)

10:55
12/06/16
12/06
10:55
12/06/16
10:55
Conference/Events
House Energy & Commerce Committee to hold a hearing »

The Oversight &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 05

    Jan

  • 10

    Jan

BOBE

Bob Evans

$46.77

1.05 (2.30%)

, JPM

JPMorgan

$82.99

-0.27 (-0.32%)

10:51
12/06/16
12/06
10:51
12/06/16
10:51
Hot Stocks
Bob Evans holder Sandell 'encouraged' by retention of financial advisor »

Sandell Asset Management,…

BOBE

Bob Evans

$46.77

1.05 (2.30%)

JPM

JPMorgan

$82.99

-0.27 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 06

    Dec

  • 06

    Dec

  • 09

    Jan

  • 13

    Jan

  • 28

    Feb

  • 14

    Jul

  • 12

    Oct

ETE

Energy Transfer Equity

$16.24

0.17 (1.06%)

10:50
12/06/16
12/06
10:50
12/06/16
10:50
Options
Notable call spreads in Energy Transfer Equity »

Notable call spreads in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$60.22

0.97 (1.64%)

, LNKD

LinkedIn

$195.41

0.16 (0.08%)

10:49
12/06/16
12/06
10:49
12/06/16
10:49
Hot Stocks
European Commission approves acquisition of LinkedIn by Microsoft »

The European Commission…

MSFT

Microsoft

$60.22

0.97 (1.64%)

LNKD

LinkedIn

$195.41

0.16 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BW

Babcock & Wilcox

$16.02

0.03 (0.19%)

10:47
12/06/16
12/06
10:47
12/06/16
10:47
Conference/Events
Babcock & Wilcox management to meet with William Blair »

Group luncheon with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

RIG

Transocean

$14.13

0.15 (1.07%)

10:47
12/06/16
12/06
10:47
12/06/16
10:47
Hot Stocks
Transocean announces approval of merger with Transocean Partners »

Transocean announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WERN

Werner

$27.90

0.2 (0.72%)

10:46
12/06/16
12/06
10:46
12/06/16
10:46
Conference/Events
Werner management to meet with Stephens »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

SNN

Smith & Nephew

$28.77

0.27 (0.95%)

10:46
12/06/16
12/06
10:46
12/06/16
10:46
Conference/Events
Smith & Nephew management to meet with Jefferies »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

RP

RealPage

$28.80

0.25 (0.88%)

10:45
12/06/16
12/06
10:45
12/06/16
10:45
Conference/Events
RealPage management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 13

    Dec

10:45
12/06/16
12/06
10:45
12/06/16
10:45
General news
The U.S. factory goods data slightly underperformed »

The U.S. factory goods…

BAC

Bank of America

$21.81

-0.03 (-0.14%)

10:44
12/06/16
12/06
10:44
12/06/16
10:44
Hot Stocks
Bank of America CEO: $53B cost-cutting target reflects 'environment we're in' »

Says "tremendous…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 13

    Jan

RP

RealPage

$28.80

0.25 (0.88%)

10:44
12/06/16
12/06
10:44
12/06/16
10:44
Conference/Events
RealPage management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 13

    Dec

MMI

Marcus & Millichap

$27.72

-0.1 (-0.36%)

10:44
12/06/16
12/06
10:44
12/06/16
10:44
Conference/Events
Marcus & Millichap management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

IT

Gartner

$101.15

0.46 (0.46%)

10:43
12/06/16
12/06
10:43
12/06/16
10:43
Conference/Events
Gartner management to meet with William Blair »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

HIBB

Hibbett Sports

$42.55

2.1 (5.19%)

10:42
12/06/16
12/06
10:42
12/06/16
10:42
Conference/Events
Hibbett Sports management to meet with Canaccord »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

ISRG

Intuitive Surgical

$636.95

0.31 (0.05%)

10:42
12/06/16
12/06
10:42
12/06/16
10:42
Technical Analysis
Intuitive Surgical falls, levels to watch »

The stock was last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

  • 07

    Dec

AOSL

Alpha & Omega

$20.51

0.43 (2.14%)

10:40
12/06/16
12/06
10:40
12/06/16
10:40
Conference/Events
Alpha & Omega management to meet with Drexel Hamilton »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

SBUX

Starbucks

$57.50

0.29 (0.51%)

10:40
12/06/16
12/06
10:40
12/06/16
10:40
Options
Option action heats up in Starbuck's weeklys »

Option action heats up in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

AIRM

Air Methods

$32.70

0.15 (0.46%)

10:39
12/06/16
12/06
10:39
12/06/16
10:39
Conference/Events
Air Methods management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

SSNLF

Samsung

, AAPL

Apple

$109.11

-0.79 (-0.72%)

10:39
12/06/16
12/06
10:39
12/06/16
10:39
Periodicals
SCOTUS sides with Samsung in smartphone battle with Apple, Reuters reports »

The U.S. Supreme Court…

SSNLF

Samsung

AAPL

Apple

$109.11

-0.79 (-0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

  • 08

    Dec

  • 13

    Mar

TASR

TASER

$28.08

0.16 (0.57%)

10:38
12/06/16
12/06
10:38
12/06/16
10:38
Conference/Events
TASER management to meet with Craig Hallum »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

ABBV

AbbVie

$61.28

0.42 (0.69%)

10:38
12/06/16
12/06
10:38
12/06/16
10:38
Hot Stocks
AbbVie says Phase 2 study PCYC-1129 found ibrutinib demonstrated efficacy »

AbbVie announced positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

P

Pandora

$13.51

0.14 (1.05%)

, SIRI

Sirius XM

$4.33

0.03 (0.70%)

10:38
12/06/16
12/06
10:38
12/06/16
10:38
Hot Stocks
Oppenheimer says buy Pandora on potential Sirius XM deal »

Shares of Pandora Media…

P

Pandora

$13.51

0.14 (1.05%)

SIRI

Sirius XM

$4.33

0.03 (0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMC

Honda

$29.29

-0.14 (-0.48%)

10:37
12/06/16
12/06
10:37
12/06/16
10:37
Upgrade
Honda rating change  »

Honda upgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.